The use of VEGF inhibitors for the treatment of cancer-related angiogenesis in patients with cancer has been associated with hypertension, proteinuria, glomerular endothelial damage, elevated circulating liver enzymes, cerebral edema, and reversible posterior leukoencephalopathy—features resembling those found in human PE and eclampsia.100, 101, 99 These studies point to the central role of sFLT1 and impaired VEGF signaling in the development of PE. This evidence concerns the gene VEGFA and cancer.